Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.17 - $1.65 $31,238 - $44,055
26,700 Added 3337.5%
27,500 $32,000
Q1 2024

May 15, 2024

SELL
$1.15 - $2.19 $114 - $219
-100 Reduced 11.11%
800 $1,000
Q4 2023

Feb 14, 2024

BUY
$0.93 - $2.35 $837 - $2,115
900 New
900 $1,000
Q2 2023

Aug 14, 2023

SELL
$1.8 - $3.19 $105,660 - $187,253
-58,700 Reduced 96.71%
2,000 $3,000
Q1 2023

May 15, 2023

BUY
$2.01 - $4.17 $122,006 - $253,119
60,700 New
60,700 $167,000

Others Institutions Holding PSNL

About Personalis, Inc.


  • Ticker PSNL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 45,918,400
  • Market Cap $253M
  • Description
  • Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or pla...
More about PSNL
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.